Allarity Therapeutics Inc (ALLR)

$1.41 +0.02 (1.44%)
Market Cap 22.12M
Revenue (ttm) 320,000.00
Net Income (ttm) -11.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,509.37%
Debt to Equity Ratio 0.21
Volume 75,300
Avg Vol 126,898
Day's Range N/A - N/A
Shares Out 15.91M
Stochastic %K 93%
Beta 0.51
Analysts Sell
Price Target $10.25

Company Profile

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a...

Industry: Biotechnology
Sector: Healthcare
Phone: 401 426 4664
Address:
123 E. Tarpon Ave., Tarpon Springs, United States
Wody
Wody Aug. 10 at 3:38 PM
$ALLR
0 · Reply
Crisley1
Crisley1 Aug. 10 at 1:52 PM
$ALLR
0 · Reply
Dizzier47
Dizzier47 Aug. 8 at 3:14 PM
$ALLR buying more on monday open, either lambos or a wagie forever
0 · Reply
Wody
Wody Aug. 7 at 10:32 PM
$ALLR anyone’s spidey senses tingling for some news next week…?!
1 · Reply
RAKIN13
RAKIN13 Aug. 6 at 8:15 PM
$ALLR news tomorrow?
2 · Reply
JustWin2025
JustWin2025 Aug. 6 at 2:15 PM
$ALLR - pls give us some news!!!
0 · Reply
rexwiggins
rexwiggins Aug. 6 at 1:48 PM
$ALLR watching but not adding
0 · Reply
Dizzier47
Dizzier47 Aug. 6 at 5:11 AM
$ALLR we gon get this
0 · Reply
Dizzier47
Dizzier47 Aug. 5 at 12:06 PM
$ALLR pop open a cold one
0 · Reply
TargasMum
TargasMum Aug. 4 at 6:22 PM
$ALLR
1 · Reply
Latest News on ALLR
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

Jul 7, 2026, 8:00 AM EDT - 4 weeks ago

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

Jun 30, 2026, 8:00 AM EDT - 5 weeks ago

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

Allarity to present trial-in-progress poster on Phase 2 stenoparib trial

2026-06-18T12:18:06.000Z - 7 weeks ago

Allarity to present trial-in-progress poster on Phase 2 stenoparib trial

Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

Jun 18, 2026, 8:00 AM EDT - 7 weeks ago

Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

May 15, 2026, 4:30 PM EDT - 3 months ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

May 8, 2026, 8:45 AM EDT - 3 months ago

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

May 5, 2026, 8:00 AM EDT - 3 months ago

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity receives notice of allowance from USPTO

2026-04-27T13:21:02.000Z - 3 months ago

Allarity receives notice of allowance from USPTO

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Mar 31, 2026, 8:00 AM EDT - 4 months ago

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity closes $20M financing for stenoparib advancement

2026-03-06T13:19:41.000Z - 5 months ago

Allarity closes $20M financing for stenoparib advancement

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Mar 6, 2026, 8:00 AM EST - 5 months ago

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Allarity doses first patients in Phase 2 trial of SCLC

2026-02-18T13:25:56.000Z - 6 months ago

Allarity doses first patients in Phase 2 trial of SCLC

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Feb 18, 2026, 8:15 AM EST - 6 months ago

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Allarity announce enrollment open for Phase 2 trial of stenoparib, temozolomide

2026-02-03T13:20:33.000Z - 6 months ago

Allarity announce enrollment open for Phase 2 trial of stenoparib, temozolomide

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

Feb 3, 2026, 8:00 AM EST - 6 months ago

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

Allarity CEO says 2026 represents an ‘inflection point’

2025-12-31T13:05:34.000Z - 7 months ago

Allarity CEO says 2026 represents an ‘inflection point’

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

Dec 31, 2025, 8:00 AM EST - 7 months ago

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

Allarity files $50M mixed securities shelf

2025-12-03T14:15:27.000Z - 8 months ago

Allarity files $50M mixed securities shelf

Allarity reports Q3 EPS (19c) vs ($7.71) last year

2025-11-14T14:06:08.000Z - 9 months ago

Allarity reports Q3 EPS (19c) vs ($7.71) last year

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

Nov 14, 2025, 9:00 AM EST - 9 months ago

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

Allarity files to sell 1.56M shares of common stock for holders

2025-09-25T21:25:29.000Z - 11 months ago

Allarity files to sell 1.56M shares of common stock for holders

Allarity presents new Phase 2 clinical data for Stenoparib

2025-09-22T12:20:54.000Z - 11 months ago

Allarity presents new Phase 2 clinical data for Stenoparib

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Sep 22, 2025, 8:00 AM EDT - 11 months ago

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

Sep 17, 2025, 8:00 AM EDT - 11 months ago

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today?

2025-08-27T01:00:00.000Z - 1 year ago

Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today?

Allarity announces FDA granted Fast Track designation to stenoparib

2025-08-26T12:05:59.000Z - 1 year ago

Allarity announces FDA granted Fast Track designation to stenoparib

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

Aug 26, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

Aug 15, 2025, 4:30 PM EDT - 1 year ago

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

Allarity initiated with a Buy at Ascendiant

2025-07-28T09:50:42.000Z - 1 year ago

Allarity initiated with a Buy at Ascendiant

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

Jul 15, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

Allarity appoints Jeff Ervin as CFO

2025-07-07T12:26:02.000Z - 1 year ago

Allarity appoints Jeff Ervin as CFO

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

Allarity gets Australian patent acceptance notice for DRP companion diagnostic

2025-06-30T14:34:35.000Z - 1 year ago

Allarity gets Australian patent acceptance notice for DRP companion diagnostic

Allarity announces second patient dosed in Phase 2 trial of stenoparib

2025-06-27T12:10:38.000Z - 1 year ago

Allarity announces second patient dosed in Phase 2 trial of stenoparib

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Jun 27, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics Announces Changes to Board of Directors

Jun 11, 2025, 4:05 PM EDT - 1 year ago

Allarity Therapeutics Announces Changes to Board of Directors

Allarity announces research collaboration with IBRI

2025-06-04T12:05:09.000Z - 1 year ago

Allarity announces research collaboration with IBRI

Allarity announces first patient enrolled in Phase 2 trial of stenoparib

2025-06-02T12:30:27.000Z - 1 year ago

Allarity announces first patient enrolled in Phase 2 trial of stenoparib

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

May 9, 2025, 4:05 PM EDT - 1 year ago

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Mar 6, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Feb 24, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Feb 6, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Jan 30, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Nov 18, 2024, 8:00 AM EST - 1 year ago

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Wody
Wody Aug. 10 at 3:38 PM
$ALLR
0 · Reply
Crisley1
Crisley1 Aug. 10 at 1:52 PM
$ALLR
0 · Reply
Dizzier47
Dizzier47 Aug. 8 at 3:14 PM
$ALLR buying more on monday open, either lambos or a wagie forever
0 · Reply
Wody
Wody Aug. 7 at 10:32 PM
$ALLR anyone’s spidey senses tingling for some news next week…?!
1 · Reply
RAKIN13
RAKIN13 Aug. 6 at 8:15 PM
$ALLR news tomorrow?
2 · Reply
JustWin2025
JustWin2025 Aug. 6 at 2:15 PM
$ALLR - pls give us some news!!!
0 · Reply
rexwiggins
rexwiggins Aug. 6 at 1:48 PM
$ALLR watching but not adding
0 · Reply
Dizzier47
Dizzier47 Aug. 6 at 5:11 AM
$ALLR we gon get this
0 · Reply
Dizzier47
Dizzier47 Aug. 5 at 12:06 PM
$ALLR pop open a cold one
0 · Reply
TargasMum
TargasMum Aug. 4 at 6:22 PM
$ALLR
1 · Reply
Wody
Wody Aug. 4 at 4:15 PM
$ALLR release the info…
1 · Reply
BetterDayzz
BetterDayzz Aug. 4 at 2:59 PM
$ALLR It’s cookin’
0 · Reply
Dizzier47
Dizzier47 Aug. 4 at 10:36 AM
$ALLR
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 4 at 6:18 AM
$ALLR yep
0 · Reply
Dizzier47
Dizzier47 Aug. 3 at 3:51 PM
$ALLR GON MAKE ME OR BREAK ME
1 · Reply
Dizzier47
Dizzier47 Aug. 3 at 6:12 AM
$ALLR moon by end of month lego
0 · Reply
Dizzier47
Dizzier47 Aug. 2 at 9:29 AM
$ALLR moonsoon
0 · Reply
Dizzier47
Dizzier47 Jul. 31 at 11:42 AM
$ALLR soon we moon
1 · Reply
JustWin2025
JustWin2025 Jul. 31 at 3:23 AM
$ALLR - wen moon?
0 · Reply
Wody
Wody Jul. 27 at 7:28 PM
$ALLR where’s the volume…
0 · Reply
jrothman22
jrothman22 Jul. 27 at 6:45 PM
$ALLR https://x.com/allaritybio/status/2081745200687239515?s=46
1 · Reply
Wody
Wody Jul. 27 at 3:19 PM
$ALLR
0 · Reply